Participated · Equity · Aug 2024

XO Life develops "Brite," a global meta-platform that consolidates digital product and therapy support so pharma and medtech companies can provide patient information, monitoring and engagement in a single infrastructure. The company emphasizes scalability by enabling many therapies and markets to use one platform instead of separate apps for each medication. XO Life works with more than 40 pharmaceutical companies, including three of the world's top ten, and plans to position Brite as a consolidated offering in early 2025. It intends to invest the new funding in AI capabilities and in processes to simplify and speed pharma onboarding across entire portfolios. XO Life focuses on B2B relationships at the interface of patients, medical professionals and the pharmaceutical industry, where long sales cycles and regulatory requirements are prominent. The company is headquartered in Munich and is using successive funding rounds to move from platform build-out to international scaling across Europe.

Participated · Series C · Aug 2024

Caresyntax offers a vendor-neutral precision surgery platform led by CEO Dennis Kogan. Its proprietary software and AI captures and analyzes large volumes of video, audio, images, device, clinical and operational data in and around the operating room to deliver actionable insights, meta-data and real-world evidence. The software and automation platform can be used live during procedures and accessed by users outside the OR via secured dedicated cloud and telehealth links. The platform aims to help surgeons and care teams improve patient outcomes, enable hospital administrators to use resources more efficiently, assist medical device companies to advance products, and support insurers in understanding and controlling risks and enabling value-based contracts. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide. The company raised $180M in Series C financing and intends to use the funds to expand operations and its development efforts. Caresyntax provides a digital surgery platform that uses proprietary software and artificial intelligence to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. The platform delivers actionable insights for care teams and longer-term analytics for stakeholders such as surgeons, and offers virtual, real-time access to outside experts. Caresyntax's software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company plans to use new funds to continue developing its platform and to advance new data solutions that support value-based care providers. The product emphasis is on improving patient outcomes through immediate and longer-term insights derived from real-world OR data. The company was founded by Dennis Kogan and Björn von Siemens. Caresyntax provides an enterprise-grade digital surgery platform that uses proprietary software and AI to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. Its platform delivers real-world evidence that care teams can use live during procedures via a telehealth link and post-procedure for benchmarking and improvement. Hospitals can use the platform to manage surgical resources more efficiently, medical device companies can advance products, and insurers can better understand risk. The software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company announced the acquisition of Syus at the close of 2019, extending its hospital footprint and analytics capabilities. Caresyntax intends to use the new funding to accelerate expansion in key markets, further R&D of its AI analytics, build out its platforms, and grow its employee base. caresyntax provides surgical intelligence and automation solutions that leverage IoT, analytics and AI to integrate data from medical devices, EHRs and other OR sources into a unified platform. Its offerings automate clinical and operational decision support for surgical teams and support outcome contributors across risk-bearing contracts. The company says its technologies are used in more than 7,000 operating rooms worldwide and support over 10 million procedures per year. Recent partnerships with organizations including Mitsubishi’s MC Healthcare, Barco Healthcare, Insel Gruppe AG and University of Wisconsin–Madison aim to expand R&D and global reach. caresyntax plans to use new capital to accelerate domestic and international growth and to further develop and deploy its surgical intelligence and automation technologies. The company works with providers, insurers and device vendors to inform device improvements, support data-driven underwriting and enable value-based contracting. Caresyntax provides a vendor-neutral platform that aggregates structured and unstructured data from operating room devices, electronic health records and other sources into unified dashboards for surgeons and hospital decision makers. Its offerings include PRIME365 OR integration and qvident surgical performance management software, which aim to reduce documentation time, automate workflows, and generate quality data for training and decision support. The company emphasizes granular analysis of surgical variation to recommend fixes that reduce readmissions, improve patient safety and streamline clinical workflows. Caresyntax reports an installed base of more than 6,000 operating rooms, supports over 10 million procedures per year and generates roughly 100 petabytes of high-fidelity data annually. It was launched in 2013 in Germany and established full-time North American operations and a headquarters in Boston in October. The company says it will use the new financing to grow its U.S. business and to develop machine learning and value-added applications for surgical risk management.

Led · Series B · Oct 2023

Neteera offers a passive, contactless patient monitoring platform that continuously captures vital signs and bio-data without cameras or device manipulation, protecting privacy. Its sensing technology is based on a maintenance-free sub-THz micro-radar on chip that eliminates the need for clothing removal or caregiver presence. The solution is FDA-cleared and targeted at strained healthcare settings and home health. In 2023 the company began selling to a large number of long-term care facilities in the U.S. and reports a significant pipeline of ordered products currently being deployed. Neteera plans to use newly raised funds to expedite production, meet demand for its platform, and recruit installation and deployment personnel. The company is led by CEO Isaac Litman and is based in Jerusalem, Israel. Neteera Technologies is a Jerusalem, Israel–based patient monitoring company led by CEO Isaac Litman. It offers an FDA-cleared continuous, contactless, passive vital-signs and bio-data monitoring solution for strained healthcare settings and home health. The sensing platform eliminates the need for device manipulation, removal of clothing, and caregiver presence. The technology is based on a safe, maintenance-free sub-THz micro-radar on-chip sensor and protects privacy by not using a camera. Neteera closed an approximately $13M Series B and intends to use the funds to accelerate sales, production and deployment of its contactless solution and to further develop features for its proprietary medical sensing platform. The company has also entered a strategic partnership with Omega Healthcare Investors to offer its technology to Omega’s healthcare operating partners.

Participated · Seed · Oct 2023

Founded in 2023 by Linus Drop and Daniel Hefel, Mannheim-based LillianCare tackles the looming shortage of general practitioners by setting up hybrid family practices that blend interdisciplinary staff in physical clinics with digital services such as telemedicine. The company has already opened five practices in Rhineland-Palatinate and Lower Saxony, areas where many family doctors are nearing retirement. Patients gain faster, nearby access to care, while physicians benefit from flexible, partially remote work models. LillianCare plans to grow aggressively, aiming to establish 400 additional practices by 2030. Beginning in 2026, the team intends to scale further through license partnerships that let independent doctors run their own clinics using LillianCare’s infrastructure. The newly raised capital will be directed primarily toward opening and equipping these new locations. The company positions itself as an impact-driven healthcare provider, emphasizing that medical decision-making remains entirely with physicians.

Participated · Series A · Jul 2023

Piur Imaging develops Piur tUS Infinity, a vendor-independent AI-driven tomographic 3D ultrasound solution that captures large regions of interest as high-resolution 3D volumes and offers semi-automatic clinical data analysis. The company claims its technology reduces inter- and intra-observer variability and can provide volumetric measurements where existing 2D ultrasound approaches only estimate. Piur has established distribution partnerships with industry players in nuclear medicine and ultrasound to deploy its solution. With the Series A funding it plans to rework and relaunch a major software update and a second-generation sensor to improve usability and performance. The company will also expand its commercial team and user base and scale in Germany, Italy, Spain, and France while initiating initial sales in the USA. Piur was founded in 2014 in Vienna by Frederik Bender and Robert Bauer.